Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
Abstract Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein recently approved for prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE). The objective of this report is to summarize results from an interim analysis of an ongo...
Main Authors: | Henriette Farkas, Marcin Stobiecki, Jonny Peter, Tamar Kinaciyan, Marcus Maurer, Emel Aygören‐Pürsün, Sorena Kiani‐Alikhan, Adrian Wu, Avner Reshef, Anette Bygum, Olivier Fain, David Hagin, Aarnoud Huissoon, Miloš Jeseňák, Karen Lindsay, Vesna Grivcheva Panovska, Urs C. Steiner, Celia Zubrinich, Jessica M. Best, Melanie Cornpropst, Daniel Dix, Sylvia M. Dobo, Heather A. Iocca, Bhavisha Desai, Sharon C. Murray, Eniko Nagy, William P. Sheridan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Clinical and Translational Allergy |
Subjects: | |
Online Access: | https://doi.org/10.1002/clt2.12035 |
Similar Items
-
Considerations for transition from subcutaneous to oral prophylaxis in the treatment of hereditary angioedema
by: Richard G. Gower, et al.
Published: (2021-10-01) -
Management of Hereditary Angioedema in North Macedonia compared to regional and Western European data
by: Vesna Grivcheva-Panovska
Published: (2020-08-01) -
Subcutaneous C1‐Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1‐INH‐HAE
by: Shimalee Andarawewa, et al.
Published: (2021-03-01) -
Mycetoma Caused by Acremonium Species in a Patient with Chronic Granulomatous Disease
by: Richard Antrobus, et al.
Published: (2016-01-01) -
Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema
by: Aygören-Pürsün E, et al.
Published: (2016-09-01)